French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in global revenues to €3.4 billion ($3.57 billion) for 2024, according to its annual financial report. Core operating profit rose 10.8% YOY to €1.109 billion ($1.165 billion), driven by strong performances across all business sectors.
Sector Breakdown
- Rare Diseases: Revenues surged 67.4% YOY to €196 million ($206 million).
- Neurosciences: Sales grew 9.2% to €700 million ($735 million).
- Oncology: Revenues climbed 7.3% YOY to €2.504 billion ($2.63 billion).
Product Highlights
Somatuline (lanreotide), a somatostatin analogue for neuroendocrine tumors, generated €1.121 billion ($1.18 billion) in sales, up 5.6% YOY. All other products achieved double-digit growth, averaging 12.2%.
Geographic Performance
- North America: €1.168 billion ($1.227 billion) in sales.
- Europe: €1.336 billion ($1.404 billion).
- Other Markets: €897 million ($943 million).-Fineline Info & Tech
Leave a Reply